Novo Nordisk shares climb after positive results for anti-obesity pill
PositiveFinancial Markets

Novo Nordisk's shares surged by approximately £9 billion after promising trial results for its new anti-obesity pill, which demonstrated significant weight loss comparable to its existing Wegovy injection. This development is crucial as the company competes with Eli Lilly to bring an effective tablet treatment to market, potentially reshaping the obesity treatment landscape and offering new hope for those struggling with weight management.
— Curated by the World Pulse Now AI Editorial System